SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have been used as the first‐line treatment of non‐small cell lung cancers (NSCLC) harboring EGFR‐activating mutations, but acquired resistance is ubiquitous and needs to be solved urgently. Here, we introduce an effective appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Mengya, Gao, Mingzhao, Xu, Yongping, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825016/
https://www.ncbi.nlm.nih.gov/pubmed/31446643
http://dx.doi.org/10.1111/cas.14180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825016/
https://www.ncbi.nlm.nih.gov/pubmed/31446643
http://dx.doi.org/10.1111/cas.14180

Ejemplares similares